Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.

Dos Santos Ramos MA, Da Silva PB, Spósito L, De Toledo LG, Bonifácio BV, Rodero CF, Dos Santos KC, Chorilli M, Bauab TM.

Int J Nanomedicine. 2018 Feb 27;13:1179-1213. doi: 10.2147/IJN.S146195. eCollection 2018. Review.

2.

Chronic lymphocytic meningitis with low CSF sugar, pulmonary infiltrate, and hilar lymphadenopathies in an immunocompetent patient.

Vázquez-Picón R, Gómez-Beldarrain M, Vicente-Olabarria I, Rodríguez-Sainz A, García-Moncó JC.

Neurol Clin Pract. 2015 Aug;5(4):360-363. doi: 10.1212/CPJ.0000000000000129. No abstract available.

3.

Virulence Factors as Targets for Anticryptococcal Therapy.

Azevedo RVDM, Rizzo J, Rodrigues ML.

J Fungi (Basel). 2016 Nov 30;2(4). pii: E29. doi: 10.3390/jof2040029. Review.

4.

Eugenol Induces Phenotypic Alterations and Increases the Oxidative Burst in Cryptococcus.

Alves JCO, Ferreira GF, Santos JR, Silva LCN, Rodrigues JFS, Neto WRN, Farah EI, Santos ÁRC, Mendes BS, Sousa LVNF, Monteiro AS, Dos Santos VL, Santos DA, Perez AC, Romero TRL, Denadai ÂML, Guzzo LS.

Front Microbiol. 2017 Dec 7;8:2419. doi: 10.3389/fmicb.2017.02419. eCollection 2017.

5.

A Call to Arms: Quest for a Cryptococcal Vaccine.

Caballero Van Dyke MC, Wormley FL Jr.

Trends Microbiol. 2018 May;26(5):436-446. doi: 10.1016/j.tim.2017.10.002. Epub 2017 Nov 2. Review.

PMID:
29103990
6.

Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Bellmann R, Smuszkiewicz P.

Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12. Review.

7.

Necrotizing fasciitis as the initial presentation of disseminated infection with fluconazole-resistant Cryptococcus neoformans.

Richardson TE, Lee NE, Cykowski MD, Chang SA, Powell SZ.

JMM Case Rep. 2014 Dec 1;1(4):e003608. doi: 10.1099/jmmcr.0.003608-0. eCollection 2014 Dec.

8.

Population genomics and the evolution of virulence in the fungal pathogen Cryptococcus neoformans.

Desjardins CA, Giamberardino C, Sykes SM, Yu CH, Tenor JL, Chen Y, Yang T, Jones AM, Sun S, Haverkamp MR, Heitman J, Litvintseva AP, Perfect JR, Cuomo CA.

Genome Res. 2017 Jul;27(7):1207-1219. doi: 10.1101/gr.218727.116.

9.

Normalization of Bilateral Adrenal Gland Enlargement after Treatment for Cryptococcosis.

Muraoka Y, Iwama S, Arima H.

Case Rep Endocrinol. 2017;2017:1543149. doi: 10.1155/2017/1543149. Epub 2017 Mar 26.

10.

Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod.

Seto H, Nishimura M, Minamiji K, Miyoshi S, Mori H, Kanazawa K, Yasuda H.

Intern Med. 2016;55(22):3383-3386. Epub 2016 Nov 15.

11.

Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species Complex.

Aminnejad M, Cogliati M, Duan S, Arabatzis M, Tintelnot K, Castañeda E, Lazéra M, Velegraki A, Ellis D, Sorrell TC, Meyer W.

PLoS One. 2016 Oct 20;11(10):e0163955. doi: 10.1371/journal.pone.0163955. eCollection 2016.

12.

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.

Okamoto K, Proia LA, Demarais PL.

Case Rep Infect Dis. 2016;2016:4642831. Epub 2016 Sep 14.

13.

Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.

Mamuye AT, Bornstein E, Temesgen O, Blumberg HM, Kempker RR.

Am J Trop Med Hyg. 2016 Oct 5;95(4):786-792. Epub 2016 Aug 15.

14.

Silver adducts of four-branched histidine rich peptides exhibit synergistic antifungal activity.

Leng Q, Woodle MC, Liu Y, Mixson AJ.

Biochem Biophys Res Commun. 2016 Sep 2;477(4):957-962. doi: 10.1016/j.bbrc.2016.07.008. Epub 2016 Jul 4.

15.

Evolution of Cryptococcal Antigen Testing: What is new?

Nalintya E, Kiggundu R, Meya D.

Curr Fungal Infect Rep. 2016 Jun;10(2):62-67. doi: 10.1007/s12281-016-0256-3. Epub 2016 Apr 12.

16.

DAP12 Inhibits Pulmonary Immune Responses to Cryptococcus neoformans.

Heung LJ, Hohl TM.

Infect Immun. 2016 May 24;84(6):1879-86. doi: 10.1128/IAI.00222-16. Print 2016 Jun.

17.

Enhanced virulence of Histoplasma capsulatum through transfer and surface incorporation of glycans from Cryptococcus neoformans during co-infection.

Cordero RJ, Liedke SC, de S Araújo GR, Martinez LR, Nimrichter L, Frases S, Peralta JM, Casadevall A, Rodrigues ML, Nosanchuk JD, Guimaraes AJ.

Sci Rep. 2016 Feb 24;6:21765. doi: 10.1038/srep21765.

18.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.

19.

Primary Larynx Cryptococcus neoformans Infection: A Distinctive Clinical Entity.

Bergeron M, Gagné AA, Côté M, Chênevert J, Dubé R, Pelletier R.

Open Forum Infect Dis. 2015 Oct 26;2(4):ofv160. doi: 10.1093/ofid/ofv160. eCollection 2015 Dec.

20.

Supplemental Content

Support Center